Rechercher des projets européens

14 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 

PROMOTING ACTIVE AGEING: FUNCTIONAL NANOSTRUCTURES FOR ALZHEIMER’S DISEASE AT ULTRA-EARLY STAGES. (PANA)

Date du début: 1 mars 2016, Date de fin: 28 févr. 2021,

Alzheimer’s disease (AD) is the leading cause of dementia and loss of autonomy in the elderly, implying a progressive cognitive decline and limitation of social activities. Progressive aging of EU population will increase the magnitude of this problem in the next decades. Currently, there is not an effective method for the early diagnosis of AD. Therefore, there is an urgent need to develop new ef ...
Voir le projet

 11

 TERMINÉ 

Personalised Risk assessment in febrile illness to Optimise Real-life Management across the European Union (PERFORM)

Date du début: 1 janv. 2016, Date de fin: 31 déc. 2020,

The management of febrile patients is one of the most common and important problems facing healthcare providers. Distinction between bacterial infections and trivial viral infection on clinical grounds is unreliable, and as a result innumerable patients worldwide undergo hospitalization, invasive investigation and are treated with antibiotics for presumed bacterial infection when, in fact, they ar ...
Voir le projet

 19

 TERMINÉ 

Applied Public-Private Research enabling OsteoArthritis Clinical Headway (APPROACH)

Date du début: 1 juin 2015, Date de fin: 30 nov. 2020,

The problem: finding the right patient for the right treatmentDespite a large and growing disease burden in osteoarthritis (OA), many pharmaceutical companies have de-emphasized or even abandoned OA drug development due to perceived hurdles. Crucial in this is the lack of appropriate outcome measures that can robustly identify patient benefit from a specific therapy. The lack of specific and sensi ...
Voir le projet

 25

 TERMINÉ 

REgenerative Stem cell therapy for STroke in Europe (RESSTORE)

Date du début: 1 sept. 2015, Date de fin: 31 août 2020,

Stroke is the second leading cause of death in the world population. When not fatal, stroke often results in disability, due to motor and cognitive impairments, and secondary health problems affecting not only patients but also their families. Building on emerging preclinical and pilot clinical evidences, RESSTORE will focus on the clinical assessment of regenerative cell therapy to improve stroke ...
Voir le projet

 29

 TERMINÉ 

ACTivating InnoVative IoT smart living environments for AGEing well (ACTIVAGE)

Date du début: 1 janv. 2017, Date de fin: 30 juin 2020,

ACTIVAGE is a European Multi Centric Large Scale Pilot on Smart Living Environments. The main objective is to build the first European IoT ecosystem across 9 Deployment Sites (DS) in seven European countries, reusing and scaling up underlying open and proprietary IoT platforms, technologies and standards, and integrating new interfaces needed to provide interoperability across these heterogeneous ...
Voir le projet

 50

 TERMINÉ 

Magnetic DIagnostic Assay for neurodegenerative diseases (MADIA)

Date du début: 1 janv. 2017, Date de fin: 31 déc. 2019,

MADIA aims at realizing a versatile and cheap diagnostic device based on magnetoresistive sensors, microfluidic device, ultra–small Magnetic Nanoparticles (MNPs) and advanced bio-chemical functionalization methods for the early and ultrasensitive in vitro detection of biomarkers trustfully associated with 2 incurable neurodegenerative diseases: Alzheimer’s Disease (AD) and Parkinson Disease (PD). ...
Voir le projet

 10

 TERMINÉ 

A EUropean study on effectiveness and sustainability of current Cardiac Rehabilitation programmes in the Elderly (EU-CaRE)

Date du début: 1 mai 2015, Date de fin: 30 avr. 2019,

Cardiovascular diseases (CVD) cause over 4 million deaths in Europe each year and mass disability: within the coming decades the disability-adjusted life years (DALYs) estimate is expected to rise from a loss of 85 million DALYs in 1990 to a loss of 150 million DALYs globally in 2020. Moreover, patient numbers are expected to rise rapidly in the next decades, due to an ageing society such that th ...
Voir le projet

 11

 TERMINÉ 

Platform foR European Preparedness Against (Re-)emerging Epidemics (PREPARE)

Date du début: 1 févr. 2014, Date de fin: 31 janv. 2019,

Far from receding, the threats posed by infections with epidemic potential grow ever greater. Although Europe has amongst the best healthcare systems in the world, and also the world’s supreme researchers in this field, we lack co-ordination and linkage between networks that is required to respond fast to new threats. This consortium of consortia will streamline our response, using primary and sec ...
Voir le projet

 27

 TERMINÉ 

Platform for ultra-sensitive Point-of-Care diagnostics for Infectious Diseases (PoC-ID)

Date du début: 1 mai 2015, Date de fin: 30 avr. 2018,

The aim of the PoC-ID project is to develop new micro- and nanoelectronic-based sensing and integration concepts for advanced miniaturised in vitro diagnostic devices. The project addresses the increasing demand for rapid and ultra-sensitive point-of-care diagnostics to reduce healthcare costs and increase the quality of life with a focus on infectious diseases, one of the world’s leading causes o ...
Voir le projet

 13

 TERMINÉ 

The genetic basis of meningococcal and other life threatening bacterial infections of childhood (EUCLIDS)

Date du début: 1 déc. 2011, Date de fin: 31 mai 2017,

Bacterial infection is the major cause of disability and death in children worldwide. We will use meningococcal disease (MD) as a model to understand genetic factors underlying susceptibility and severity of childhood bacterial infection which will then be applied to other childhood infections. We have established cohorts of patients with MD in Central and Southern Europe (CE,SE), UK and Africa as ...
Voir le projet

 16

 TERMINÉ 

Open Project for the European Radiation Research Area (OPERRA)

Date du début: 1 juin 2013, Date de fin: 31 mai 2017,

"Within the OPERRA project, it is proposed that the MELODI Association, as a well-advanced network, takes the lead in establishing the necessary structures able to manage the long-term European research programmes in radiation protection, also taking advantage of the valuable experience gathered through the DoReMi network of excellence. Whilst in fields adjacent to low-dose risk research (radioeco ...
Voir le projet

 71

 TERMINÉ 

Fabrication and Functionalization of BioMedical Microdevices (FaBiMed)

Date du début: 2 sept. 2013, Date de fin: 1 sept. 2016,

The aim of FaBiMed proposal is to improve and develop new manufacturing techniques, based on micromoulding, specific for biomedical microdevices. The project will be to reducing the cost of mass production of diagnosis and therapeutic micro devices which have a common problematic: medium sized batches, customization needs, micron-scale geometrical features. These include optofluidic sensors (MIR t ...
Voir le projet

 12

 TERMINÉ 

Studies on a cohort of Serbian children exposed to x-irradiation to determine the contribution of the non-coding genome to susceptibility at low doses (DARK.RISK)

Date du début: 1 oct. 2012, Date de fin: 31 mars 2016,

"The epidemiological study of Tinea capitis (ringworm) patients has proven useful for the study of carcinogenic effects of low dose radiation. In Dark.risk we will develop a new epidemiological cohort based upon the 24 000 cases irradiated in childhood that we will document to create the Serbian Registry of Tinaea Capitis Children (SRTCC). Unlike many other epidemiological cohorts SRTCC can be use ...
Voir le projet

 5

 TERMINÉ 

Optimisation of treatment with off-patent antimicrobial agents of ventilator-associated pneumonia (VAP) (MagicBullet)

Date du début: 1 janv. 2012, Date de fin: 31 déc. 2015,

Background. Ventilator-associated pneumonia (VAP) is one of the most common and severe hospital-adquired infections, and multidrugresistant gram-negative bacilli (MDR-GNB) constitute the main etiology in many countries. Inappropriate empiric antimicrobial treatment is associated with increased mortality. In this context, the empirical treatment of choice for VAP is unknown. Colistin, and “old” dru ...
Voir le projet

 11